Who are Placebo to Alendronate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sodium monofluorophosphate toothpaste, Marketed Cavity Protection Toothpaste, Ibandronate (SB743830HD), Sodium Fluoride Dentifrice, sodium fluoride calcium fluoride, nano-hydroxyapatite varnish.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-alendronate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Alendronate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Alendronate (Placebo to Alendronate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Osteoporosis.

phase 3 Bisphosphonate Hydroxyapatite Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Alendronate (Placebo to Alendronate) — Amgen. Alendronate works by inhibiting osteoclast-mediated bone resorption.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Alendronate TARGET	Placebo to Alendronate	Amgen	phase 3	Bisphosphonate	Hydroxyapatite
Sodium monofluorophosphate toothpaste	Sodium monofluorophosphate toothpaste	Procter and Gamble	marketed	Fluoride toothpaste	Tooth enamel hydroxyapatite; bacterial enolase
Marketed Cavity Protection Toothpaste	Marketed Cavity Protection Toothpaste	Procter and Gamble	marketed	Fluoride-based remineralizing agent	Tooth enamel hydroxyapatite; oral bacterial metabolism
Ibandronate (SB743830HD)	Ibandronate (SB743830HD)	GlaxoSmithKline	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Sodium Fluoride Dentifrice	Sodium Fluoride Dentifrice	Procter and Gamble	marketed	Fluoride topical agent	Tooth enamel hydroxyapatite; bacterial enolase
sodium fluoride calcium fluoride	sodium fluoride calcium fluoride	University of Pernambuco	marketed	Fluoride supplement / dental caries preventive	Hydroxyapatite crystal structure; bacterial glycolytic enzymes
nano-hydroxyapatite varnish	nano-hydroxyapatite varnish	Nisreen Ibrahim khan	marketed	Remineralizing agent	Tooth enamel (hydroxyapatite crystal structure)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Alendronate — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-alendronate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab